Figure 6. The in vivo anti-tumor activity by AT406 or plus OSI-027.

Female nude mice bearing HepG2 tumors were treated with AT406 (50 mg/kg body weight, oral gavage, once every two days) and/or OSI-027 (10 mg/kg body weight, oral gavage, once every two days) for a total of 16 days (n = 10 per group), tumor volumes (in mm³, A) and mice body weights (in grams, C) were recorded every 4 days for a total of 24 days. Estimated daily tumor growth (in mm³ per day, B) was also presented. Two days after initial treatment, HepG2 tumors were isolated (one tumor per group), expressions of listed proteins in tumor tissues were tested by Western blotting assay (D). Relative expressions of cIAP-1, XIAP, Cle-Caspase-3, and Mcl-1 were quantified (vs. Erk1/2, D). S6K1 phosphorylation (vs. regular S6K1) was also quantified (D).*indicated statistically significant differences as compared to “Vehicle” group. ^#indicated statistically significant differences as compared to “AT406” only group. ^##indicated statistically significant differences as compared to “OSI-027” only group.